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Abstract
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Mutations in mitochondrial aminoacyl-tRNA synthetases are an increasingly recognized cause of
human diseases, often arising in individuals with compound heterozygous mutations and
presenting with system-specific phenotypes, frequently neurologic. FARS2 encodes mitochondrial
phenylalanyl transfer RNA synthetase (mtPheRS), perturbations of which have been reported in 6
cases of an infantile, lethal disease with refractory epilepsy and progressive myoclonus.
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Here we report the case of juvenile onset refractory epilepsy and progressive myoclonus with
compound heterozygous FARS2 mutations. We describe the clinical course over 6 years of care at
our institution and diagnostic studies including electroencephalogram (EEG), brain magnetic
resonance imaging (MRI), serum and cerebrospinal fluid analyses, skeletal muscle biopsy
histology, and autopsy gross and histologic findings which include features shared with AlpersHuttenlocher syndrome, Leigh syndrome, and a previously published case of FARS2 mutation
associated infantile onset disease. We additionally present structure-guided analysis of the relevant
mutations based on published mitochondrial phenylalanyl transfer RNA synthetase and related
protein crystal structures as well as biochemical analysis of the corresponding recombinant mutant
proteins.
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Introduction
Defects in nuclear genes encoding mitochondrial aminoacyl-tRNA synthetases (mt-aaRS)
are increasingly linked to a variety of pediatric and adult onset disorders1, many with
relative selectivity of organ systems affected, particularly the central nervous
system2, 3, 4, 5, 6. The mechanism by which perturbations of aminoacyl-tRNA synthetases
produce clinical phenotypes remains unclear, but is generally thought to involve a defect in
mitochondrial translation, defects in other effects of which have been linked to other human
diseases with similar phenotypes7.

Author Manuscript
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FARS2 (encoding mitochondrial phenylalanyl transfer RNA synthetase) is the nuclear
encoded aminoacyl-tRNA synthetase required for the charging of the cognate mitochondrial
tRNA with phenylalanine. Defects in this enzyme would presumably impact the expression
of the 13 mitochondrially encoded peptides, including subunits of the mitochondrial
respiratory chain8. To date, six individuals with FARS2 mutations (3 siblings with
homozygous missense mutations11, 2 siblings with compound heterozygous missense
mutations10, and 1 infant with a missense mutation and a large deletion9) have been
reported, all presenting with a clinical phenotype of infantile onset refractory epilepsy and
myoclonus (Table 1)9, 10, 11. In all cases there was a characteristic, relative specificity of the
phenotype to the central nervous system (CNS), all but one were deceased by age 3 – 24
months at the time of reporting. Of the 3 with MRI findings reported, all had abnormalities
ranging from isolated white matter abnormalities9 to cortical atrophy with putaminal signal
abnormalities10, and subdural fluid collections11. Decreased COX staining was reported in
two patients10, 11, but no ragged red fibers were observed in either of two patients with
reported muscle biopsy9, 10. Serum lactate elevations were reported in three cases9, 10. In the
sole individual for whom autopsy information was available, an Alpers-Huttenlocher-like
features were reported including brain weight <30% of normal, generalized atrophy, gliosis,
and subtotal laminar necrosis of the entire cortical ribbon10. The missense mutations
reported in compound heterozygote and homozygote patients were all highly conserved in
eukaryotic but not prokaryotic PheRS. One missense mutation from compound heterozygote
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patients is located at the ATP-binding site while the other lies at an interdomain interface.
The missense mutation of the homozygous patients maps to a distinct interdomain
interface10. Recombinant mutant proteins for each of the missense mutations demonstrated
decreased or mildly decreased catalytic efficiency and more severely impacted refolding
compared to wild type in vitro10.
Here, we report a case of a young woman with novel compound heterozygous FARS2
mutations and a CNS-specific phenotype of childhood onset refractory epilepsy, progressive
myoclonus with features in some brain regions reminiscent of Alpers-Huttenlocher
syndrome and a previously published case of FARS2 mutation associated infantile onset
disease10 as well as a region with findings similar to Leigh syndrome in addition to
characterization of enzyme kinetics and apparent binding affinities of recombinant, mutant
mtPheRs proteins.

Author Manuscript

Materials and Methods
Bioinformatics and structure-guided analysis
Multiple sequence alignments were performed using CLC Sequence Viewer Version 6.8.2
(CLC Bio, Qiagen). Crystal structures were reviewed and graphics created using Pymol12.
Functional assays
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Protein Expression and Purification—E. coli Rosetta (DE3) cells containing pRARE
plasmids encoding tRNAs for rare codons were transformed with either WT plasmid
pET21c-PheRS (a gift from L. Spremulli, University of North Carolina, Chapel Hill, NC,
USA) or mutant mtPheRS plasmids P85A and H135D. Point mutations were introduced by
site directed mutagenesis using the QuickChange protocol (Stratagene). Cultures were
grown at 37°C to OD = 0.8 and induced with 0.5 mM IPTG for 4 h. Cells were harvested,
sonicated and supernatant was collected after centrifugation at 25 000×g for 1 h. The
supernatant was applied to a TALON metal affinity resin column (Clontech), followed by
washing and the protein was eluted with 25 mM Tris–HCl, pH 8.0, 300 mM NaCl, 250 mM
imidazole and 10% glycerol. Fractions containing mtPheRS were checked for
electrophoretic purity by SDS–PAGE, pooled and dialyzed overnight at 4°C in 50 mM Tris–
HCl, pH 7.5, 5 mM MgCl2 and 100 mM KCl. The purified enzyme was concentrated,
adjusted to 50% (v/v) glycerol and aliquots were stored at -80°C. E. coli tRNAPhe was made
by T7 runoff transcription as previously described13; 10. DNA template for tRNA
transcription was generated from plasmids carrying tRNA genes by PCR amplification. The
tRNA was phenol chloroform extracted and purified on a DEAE sepharose column, as
described previously13, 10.
In vitro tRNA Aminoacylation—Endpoint in vitro aminoacylation was performed at
37 °C in aminoacylation buffer [100mMNa-Hepes (pH 7.2), 30mMKCl, 2mM ATP, and 10
mM MgCl2] containing 40 μM L-[14C]Phe (174 cpm pmol–1; Perkin-Elmer Lifesciences), 5
μM E. coli tRNAPhe transcript, and 100 nM mtPheRS. 8 μl aliquots were removed and
spotted on 3MM filter disks (Whatman), washed three times in 10% trichloroacetic acid,
once with 95% ethanol, and then dried. The amount of radioactivity retained was determined
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by liquid scintillation counting. Steady state kinetics for tRNAPhe were determined at 37 °C
as described previously with concentrations of in vitro transcribed E. coli tRNAPhe varying
between 0.1 and 5 μM and enzyme added to a final concentration of 100 nM13.
ATP-PPi Exchange—ATP-PPi exchange rate for amino acid activation was determined
according to standard methods as previously described13. Reactions were carried out at
37 °C in a medium containing 100 mM Na-Hepes (pH 7.2), 30 mM KCl, 10 mM MgCl2, 2
mM NaF, 2 mM ATP, 2 mM [32P]PPi (2 cpm/pmol), Phe (15 μM), and 50 nM mtPheRS.
After 1–5 min, 25 μl of the reaction were removed and added to a solution containing 1%
charcoal, 5.6% HClO4, and 75 mM PPi. The charcoal-bound ATP was filtered through a 3
MM Whatman filter discs under vacuum and washed three times with 5 ml of water and
once with 5 ml of ethanol. The filters were dried, and the radioactivity content was
determined by liquid scintillation counting.

Author Manuscript

Thermostability Assa—To assay protein stability, active fractions of 5 μM of all the
protein samples were incubated at 37 °C. Enzyme activity was monitored by active-site
titration and was performed in 50-μL reaction mixtures containing 100 mM Na-Hepes (pH
7.2), 30 mM KCl, 10 mM MgCl2, 2 mM ATP, 40 μM L-[14C]Phe (174 cpm pmol–1).
Pyrophosphatase was also added to ensure a unidirectional formation of aminoacyl
adenylate. The reaction was initiated by the addition of mtPheRS to a reaction mixture
preincubated at 37 °C for 5 min. After addition of the enzyme, the reaction was performed
for 10 min at 37 °C and then filtered through a nitrocellulose membrane (PROTRAN BA85;
Whatman) prewashed with cold 0.5× aminoacylation buffer. The filters were then washed
with 3 mL of cold 0.5× aminoacylation buffer and dried at 80 °C for 15 min. The amount of
radioactivity retained was quantified by liquid scintillation counting.

Author Manuscript

Patient studies
Transient elevations of serum lactate were noted as high as 6.4mmol/L (normal range 0.5-2.2
mmol/L). Muscle biopsy included examination of skeletal muscle of the right thigh using
hematoxylin and eosin stain, modified Gomori's trichrome, NADH reductase, oil red O,
PAS, COX/SDH and ATPase (at pH 4.3, 4.6, and 9.4) stains as well as electron microscopy
by standard methods. Microscopic analysis of formalin-fixed brain tissue was performed
using hematoxylin, eosin, and luxol blue stains per standard methods.

Author Manuscript

Spectrophotometeric analysis of oxidative phosphorylation, skin fibroblast pyruvate
dehydrogenase and pyruvate carboxylase activity, and butyrobetaine levels were performed
at the Center for Inherited Disorders of Energy Metabolism (CIDEM, Case Western Reserve
University). Assessment of mitochondrial DNA content of skeletal muscle was performed by
qPCR analysis at Baylor University.

Results
Genetic findings
Dual genome panel by massively parallel sequencing (Baylor College of Medicine –
MitomeNGS) revealed three nuclear variants of unknown significance and two
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mitochondrial variants of unknown significance. Nuclear variants included two mutations in
FARS2: c.253C>G (p.P85A, exon 2) and c.403C>G (p.H135D, exon2) as well as a single
missense mutation in the pyruvate carboxylase gene PC, c.2786C>G (p.A929G, exon 20).
The PC variant was predicted to be benign due to only moderate evolutionary conservation
of Alanine-929 and inconsistency with the above reported clinical phenotype. A whole
exome sequencing study was also performed (GeneDx, Gaithersburg, MD) that confirmed
the two variants in the FARS2 gene, and demonstrated compound heterozygosity, with one
allele inherited from each parent. No other significant findings were found by whole exome
sequencing.
Bioinformatics and structure-guided analysis
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To better understand potential biologic implications of the FARS2 mutations identified,
bioinformatics and crystal structure-guided analysis were undertaken. Multiple sequence
alignments of orthologous enzymes from mouse, chicken, amphibian, insect, yeast, and
bacterial species were performed and reveal that the residues affected by the missense
mutations are highly conserved through evolution, including in Escherichia coli (figure 1).
Notably, the mutations identified each convert the amino acid in question to a residue with
distinct biochemical properties. Proline-85, the residue with the most restrictive main chain
conformations, is mutated to an alanine with both a greater number of potential main chain
conformations and a more positive hydropathy score14. Likewise, histidine-135 is mutated to
an aspartate, producing a complete charge reversal of the side chain. Review of the
published crystal structure of the mtPheRS-Phe-AMP complex15 identifies proline-85 as a
buried residue while the side chain of histidine-135 is exposed. Both residues lie within the
larger “catalytic domain,” though neither contacts the Phe-AMP moiety within the active site
(figure 2a, 4b). Proline-85 constitutes the N-terminal most residue of the “Motif 1” alpha
helix that, interestingly, is required for oligomerization of class II aminoacyl-tRNA
synthetases and is speculated to perform other functions as well, though its significance in
mtPheRs, which functions as a monomer is unclear. Histidine-135 forms part of an alpha
helix within the region connecting Motif 1 and Motif 2, the second of three highly conserved
structural elements common to class II aaRSs. In the crystal structure of the orthologous
protein T. thermophilus-PheRS-bound to tRNAPhe, this conserved inter-motif region forms
one of two catalytic domain loops that associate with the acceptor stem of the tRNA
molecule16 (figure 2c). Of note, the T. thermophilus enzyme is a class II enzyme that like
class I enzymes charges the 2′OH group (as opposed to the 3′-OH group) of the terminal
tRNA ribose and is composed of two alpha-beta subunit heterodimers, in contrast to human
mtPheRs which is monomeric but shares significant sequence homology with the alpha
subunit of T. thermophilus PheRS.

Author Manuscript

Functional assays
To assess the impact of the identified P85A and H135D substitutions on enzyme function,
we expressed and purified recombinant mutant mtPheRS proteins in E. coli per established
protocols13. End point aminoacylation reactions indicated that P85A mtPheRS charges
tRNA very similarly to WT, but H135D demonstrated severe aminoacylation deficiency
(figure 3). Determination of the steady-state kinetics for tRNA revealed that mutant P85A
has a two-fold increase in catalytic efficiency when compared to WT, while kinetic
J Child Neurol. Author manuscript; available in PMC 2017 August 01.
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parameters for H135D were unable to be determined using standard techniques, reinforcing
the previously observed aminoacylation deficiency (figure 3). To better understand the cause
of this aminoacylation deficiency, we performed end-point pyrophosphate exchange
experiments. At a phenylalanine concentration of 15 μM, twice the reported KM for human
mtPheRS, mutant P85A is unable to produce a measurable amount of activity, suggesting
that the Km of P85A for Phenylalanine is higher than the reported WT value. H135D
mtPheRS showed a moderate amount of activity, suggesting that the observed
aminoacylation deficiency is likely due to a defect in tRNA binding and not amino acid
activation (figure 3).

Author Manuscript

The stability of WT and mutant proteins was assessed by active site titration after incubation
at either room temperature or 37 °C. At room temperature, neither mutation has a
measurable impact on protein stability. However, when tested at 37 °C, mutant P85A
appears to have decreased stability when compared to WT (figure 3a, 3b).
Clinical Phenotype

Author Manuscript

The patient was the second child of healthy, non-consanguineous parents born without
complication at 38 weeks gestation via normal spontaneous vaginal delivery. The pregnancy
was complicated by gestational diabetes; the perinatal period was unremarkable. She was
noted to have no major dysmorphic features. As an infant she was noted to have both motor
and speech delays, first walking independently at 17 months, running at 24 months, and
requiring a gait belt for safe ambulation at 5 years of age. Fine motor delays were likewise
noted through school age. She spoke her first word at age 3.5 years. Her parents reported
that her language skills plateaued at age 5-7 years at which point she was speaking in 3-4
word sentences with frequent grammatical errors. Paucity of speech and marked word
retrieval difficulties were noted at age 9 years, at which time her neurologic exam revealed
no focal findings beyond the aforementioned developmental delays.

Author Manuscript

Her first seizure, a prolonged generalized tonic-clonic convulsion, occurred at 8 years of age
at which time antiepileptic therapy was initiated. Electroencephalogram (EEG) at age 9
years revealed mild background slowing in full wakefulness, as well as frequent epileptiform
discharges without clinical correlate, including 3.0-3.5 Hertz (Hz) spike and slow wave
discharges with bifrontal predominance, frequent runs of semi-rhythmic generalized 3 Hz
slowing maximal over the left frontal region, and frequent runs of irregular sharp-slow wave
activity, predominantly occurring over the right posterior quadrant. These discharges
increased in frequency with sleep, occupying 65-70% of her sleep record. This initially
responded to high-dose (1 mg/kg) diazepam with significant improvement of her EEG and
some improvement in her speech and motor skills. Her EEG, however, again worsened with
increasingly frequent bursts of generalized 3-4 Hz spike and wave activity in wakefulness
and increasingly frequent generalized spikes in sleep. Her epilepsy both evolved and
progressed, despite management with multiple antiepileptic medications (including
valproate, with no resultant liver dysfunction) with focal seizures and epilepsia partialis
continua occurring with increased frequency starting at 10 years of age. At age 13, she
developed status epilepticus and progressed to have multiple subsequent events of status
epilepticus that proved refractory to standard medical management, two experimental
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medical trials, the ketogenic diet, and corpus callostomy. This progression of her epilepsy
was accompanied by the development and progressive worsening of non-epileptic
myoclonus. Notably, the corpus callostomy was complicated by subdural fluid collection
requiring external ventricular drain placement. MRI brain at that time revealed extensive
areas of abnormal T2 hyperintensity in the frontal lobes (right greater than left), anterior
cingulate gyri, left superior frontal gyrus, bilateral temporal lobes, and left cerebellar cortex
in the setting of recent seizure. MR spectroscopy in the left basal ganglia region
demonstrated an unremarkable metabolic spectrum. Repeat multi voxel MR spectroscopy of
the bilateral cerebral hemispheres one year later also showed normal metabolite ratios.

Author Manuscript
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Despite a notable absence of disease process in any other organ or system, her neurologic
status progressively deteriorated throughout this time. She had a mild decline in skills from
ages 9-10 after an initial improvement following diazepam administration, and further
decline with her convulsive seizures beginning at age 10. The patient's neurological status
precipitously declined after the onset of her initial episode of status epilepticus at age 13
and, 10 days prior to death at the age of 15 years, her neurologic exam was notable for
inability follow commands or track faces, bilaterally unreactive pupils, near-continuous
myoclonus of the right face, arm, and leg, absence of purposeful movement, and up-going
toes bilaterally. Repeat MRI brain performed 2 months prior to death demonstrated the
presence of the known fluid collection as well as T2 hyperintensity within the left caudate
and left medial temporal lobe, and the right medial occipital lobe along the superior bank of
the right calcarine sulcus with encephalomalacia of the calcaravis (figure 4). EEG performed
weeks prior to death revealed generalized, irregular theta and delta background slowing and
near-continuous bi-hemispheric independent and synchronous epileptiform discharges over
the fronto-temporal regions with shifting side predominance, at times corresponding to
myoclonus, but more often not synchronous with the clinical myoclonus. She was
hospitalized with likely pneumonia and urinary tract infections and died after being found
apneic with pulseless arrest. An autopsy was performed.
Enzymatic, histological, and autopsy findings

Author Manuscript

Skeletal muscle biopsy was obtained at age 14 years and notable for predominantly type 2
fiber atrophy with rounded, atrophic fibers scattered throughout with rare regenerative fibers
but without type grouping on H&E, ATPase PH 4.3, 4.6, and 9.4 stains. There was no
evidence of inflammation or myonecrosis. NADH staining showed targetoid fibers.
Gomoritrichome, PAS, and oil red O stains demonstrated normal patterns of staining.
Combined COX/SDH stain was unremarkable. Electron microscopy revealed fibers with
focal myofibrillary disarray, many myelin figures, abundant enlarged and swollen
mitochondria containing glycogen and no inclusions (supplemental figure 1).
Polargraphic analysis of oxidative phosphorylation performed at the Center for Inherited
Disorders of Energy Metabolism (CIDEM, Case Western Reserve University) demonstrated
normal activity of Complexes I-IV (frozen specimen). Mitochondrial DNA content of
skeletal muscle (qPCR analysis, performed at Baylor University) was reported at 61% of
control (within normal). Normal pyruvate dehydrogenase, pyruvate carboxylase activity was
noted in skin fibroblasts. “Markedly decreased” butyrobetaine, suggestive of a defect in
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carnitine biosynthesis was noted in the same specimen but these findings are likely
attributable to the patient's therapeutic ketogenic diet.
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Autopsy gross specimens revealed a normal sized heart, enlarged liver (1960gm, normal
1500-1800gm), superficial hemorrhagic necrosis of the colon, and a small brain (830g,
normal 1250-1400 g; 1.4% TBW). Microscopic analysis of brain and spinal cord revealed a
diffuse, predominantly cortical, as well as subcortical process characterized by laminar
cortical neuron loss and gliosis, diminished subcortical white matter and descending
corticospinal tracts. The most severely affected regions included the bilateral frontoribital
cortices and the bilateral primary visual cortices. In frontorbital cortex there was almost
complete absence of neurons, excessive gliosis, pale white matter, and fragmenting of the
cortical layers. The primary visual cortex is notable for a devastated line of Genari, almost
complete absence of neurons, excessive gliosis, pale white matter, and fragmenting of the
cortical layers extending through cortical layer 5. Notably, a large autopsy series of 32
patients with Alpers-Huttenlocher syndrome (a progressive degenerative encephalopathy
related to polymerase gamma mutations) has previously reported characteristic findings of
macroscopic cortical thinning, microscopic spongiosis with neuronal loss and astrocytosis
that is most severe in the occipital lobe17, 18. Similar findings were also reported in an infant
with FARS2 mutations and progressive myoclonus epilepsy10. Additionally, a small region
of spongiform change was noted in the right thalamus (figure 5) which was reminiscent of
the spongiform lesions with relative neuronal sparing that have been reported in the basal
ganglia of patients with Leigh syndrome bilaterally19, though this finding was notably
unilateral.

Discussion
Author Manuscript
Author Manuscript

Here, we report a case of compound heterozygous FARS2 mutations in association with
childhood onset refractory epilepsy, progressive myoclonus, cortical necrosis similar that
seen on autopsy in Alpers-Huttenlocher syndrome as well as a previously reported case of
FARS2 mutation-associated infantile onset disease, and limited basal ganglia spongiform
findings similar to those observed in Leigh syndrome. We additionally present
bioinformatics and biochemical data to support a causal link. The clinical course,
neuroimaging, and neuropathological findings10 we report are strikingly similar to cases
described in association with distinct FARS2 mutations in two previous publications10, 11,
with the exception of age of onset, supporting a genetic association while suggesting an
attenuated phenotype in this case. Together, these data support a distinct neuropathologic
process related to perturbations of mtPheRS function. This report underscores the
phenotypic variability associated with FARS2 mutations and highlights the utility of genetic
testing in cases of severe, refractory epilepsy and developmental delay.
The data presented here provides a plausible explanation for pathogenicity of the FARS2
mutations observed. Taken together, the kinetic assays support a deficiency in the activation
of amino acid for P85A, and a deficiency in the transfer of activated amino acid to tRNA for
H135D mtPheRS. Additionally, P85A mtPheRS proteins demonstrated decreased stability at
body temperature.
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Because proline-85 is buried and surrounded by 5 aromatic residues within a 5Å radius
(histidine-48, tyrosine-288, phenylalanine-296, phenylalanine-303, and phenylalanine-307),
it is conceivable that perturbation of this residue might impact the stability of tertiary
structural elements. Regarding the H135D substitution, review of the tRNAPhe bound T.
thermophilus PheRS structure reveals that the sidechain hydroxyl group of tyronsine-267
lies within 3.5Å of a histidine-135 nitrogen, creating the possibility of a weak electrostatic
interaction that might influence the tertiary structure of two loops that surround the acceptor
stem of the tRNA. Disruption of such an interaction by charge reversal at the 135 position
could potentially interfere with the binding of the acceptor stem, a possibility supported by
experiments with recombinant mutant proteins. Presumably, these defects are each less
potent than those observed in previously published cases.

Author Manuscript
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Two features of interest are raised by this case. This case represents compound heterozygous
mutations of a mt-aaRS, which has been seen in a preponderance of reports linking mt-aaRS
mutations and clinical phenotypes, perhaps due to a frequently embryonic lethal
homozygous phenotype in the case of most mt-aaRS mutations1 Additionally, despite
variation in severity of clinical presentation and duration of illness (presumably sufficient to
impact other organ systems), the apparent nervous system-specificity of published
phenotypes associated with FARS2 perturbations is preserved. Similar tissue or organ
system specificities have been noted with genetic perturbation of other mitochondrial mtaaRS2, 3, 4, 5, 6. It remains to be determined whether this is a result of a relative but
differential impact on the expression of specific mitochondrially encoded peptides or the
crossing of a threshold of generalized organelle dysfunction to which a given tissue—
particularly nervous system tissues—might be more sensitive. Further work is required to
more precisely delineate the pathogenic mechanisms underlying mutations in mt-aaRS
proteins as well as all diseases affecting mitochondrial translation.
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Figure 1. Multiple sequence alignment of orthologous proteins
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Multiple sequence alignment of N-terminal mitochondrial phenylalanyl transfer RNA
synthetase peptide sequences from multiple species. Conserved residues are presented in
green. The location of the mutations carried by the patient are boxed in red (proline-85) and
blue (histidine-135). Both residues are highly conserved through bacterial species.
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Figure 2. Structure-guided analysis of FARS2 mutations
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Structure-guided analysis of FARS2 mutations. Phe-AMP bound FARS2 quarternary
structure with domains labeled (PBD id 3CMQ), the locations of proline-85 and
histidine-135 are highlighted in red and blue, respectively (A). proline-85 is buried within
several aromatic residues (B). histidine-135 is located within conserved inter-motif region
forming one of two catalytic domain loops which associate with the acceptor stem of the
tRNA molecule in the crystal structure of the orthologous protein T. Thermophilus-PheRSbound to tRNA-Phe (PBD id 1EIY), pictured here in cyan with orthologous domain aligned
with FARS2 in green, tRNA-Phe is drawn in yellow.
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Figure 3. Analysis of recombinant mutant enzymes
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Recombinant mutant mtPheRS proteins were expressed and purified in E. coli per
established protocols. End point aminoacylation reactions indicated that mutant P85A
mtPheRS charges tRNA very similarly to WT, but H135D demonstrated severe
aminoacylation deficiency. Determination of the steady-state kinetics for tRNA revealed that
mutant P85A has a two-fold increase in catalytic efficiency when compared to WT, while
kinetic parameters for H135D were unable to be determined using standard techniques,
reinforcing the previously observed aminoacylation deficiency. End-point pyrophosphate
exchange experiments were also performed. At a phenylalanine concentration of 15 μM,
twice the reported Km for human mtPheRS, mutant P85A is unable to produce a measurable
amount of activity, suggesting that the Km of P85A for phenylalanine is higher than the
reported WT value. Mutant H135D mtPheRS showed a moderate amount of activity,
suggesting that the observed aminoacylation deficiency is likely due to a defect in tRNA
binding and not amino acid activation. The stability of WT and mutant proteins was assessed
by active site titration after incubation at either room temperature or 37 °C. At room
temperature, neither mutation has a measurable impact on protein stability. However, when
tested at 37 °C, mutant P85A appears to have decreased stability when compared to WT.
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Figure 4. MRI brain

MRI brain performed at age 15 years, 2 months prior to death revealing T2 hyperintensity
within the left caudate and left medial temporal lobe, and the right medial occipital lobe
along the superior bank of the right calcarine sulcus with encephalomalacia of the calcaravis.
Notably, earlier corpus callostomy for refractory seizures was complicated by the right
subdural fluid collection also seen in this image, requiring external ventricular drain
placement.
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Figure 5. Microscopic analysis of brain and spinal cord on autopsy

Microscopic analysis of the brain and spinal cord revealed a diffuse, predominantly cortical,
as well as subcortical process characterized by laminar cortical neuron loss and gliosis, with
the the primary visualcortex, seen in low (A) and high (B) power, and the lateral occipital
cortex, seen in low (C) and high (D) power markedly affected. A single focal region of
spongiform change was observed in the thalamus, shown at low (E) and high (F) power.
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Summary of Pathologic Findings
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Summary of autopsy brain histology features found in the case presented, a previously published case of
infantile onset FARS2 mutation associated disease, Alpers-Huttenlocher Syndrome, and Leigh Syndrome
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